Richard Douglas Buys 10,000 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

Share on StockTwits

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Director Richard Douglas purchased 10,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $6.03 per share, for a total transaction of $60,300.00. Following the purchase, the director now owns 70,000 shares in the company, valued at approximately $422,100. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Richard Douglas also recently made the following trade(s):

  • On Tuesday, September 10th, Richard Douglas purchased 20,000 shares of Aldeyra Therapeutics stock. The shares were purchased at an average price of $5.00 per share, for a total transaction of $100,000.00.

NASDAQ ALDX opened at $5.76 on Monday. The stock has a market capitalization of $161.33 million, a price-to-earnings ratio of -3.22 and a beta of 0.61. Aldeyra Therapeutics, Inc has a twelve month low of $4.31 and a twelve month high of $16.70. The stock has a 50-day moving average of $5.05 and a 200 day moving average of $6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.02. As a group, equities analysts anticipate that Aldeyra Therapeutics, Inc will post -2.01 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the business. Rhumbline Advisers raised its holdings in shares of Aldeyra Therapeutics by 17.3% during the first quarter. Rhumbline Advisers now owns 27,183 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 4,010 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new position in shares of Aldeyra Therapeutics during the first quarter valued at approximately $40,000. Strs Ohio raised its holdings in shares of Aldeyra Therapeutics by 7.5% during the second quarter. Strs Ohio now owns 71,900 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 5,000 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Aldeyra Therapeutics during the second quarter valued at approximately $30,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Aldeyra Therapeutics by 7.7% during the second quarter. Bank of New York Mellon Corp now owns 75,353 shares of the biotechnology company’s stock valued at $452,000 after acquiring an additional 5,406 shares during the last quarter. 61.26% of the stock is owned by institutional investors and hedge funds.

ALDX has been the topic of several research analyst reports. Cantor Fitzgerald set a $33.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Tuesday, June 25th. Zacks Investment Research downgraded Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 14th. Finally, ValuEngine raised Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 10th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $26.79.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Featured Article: How to execute a trade ex-dividend strategy?

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Vertex Energy  Upgraded to “Buy” by Zacks Investment Research
Vertex Energy Upgraded to “Buy” by Zacks Investment Research
Wynn Macau  Stock Rating Reaffirmed by Zacks Investment Research
Wynn Macau Stock Rating Reaffirmed by Zacks Investment Research
Wipro  Upgraded by Zacks Investment Research to “Hold”
Wipro Upgraded by Zacks Investment Research to “Hold”
Zacks: Brokerages Anticipate Paycom Software Inc  Will Post Earnings of $0.69 Per Share
Zacks: Brokerages Anticipate Paycom Software Inc Will Post Earnings of $0.69 Per Share
VoteCoin Price Tops $0.0027 on Exchanges
VoteCoin Price Tops $0.0027 on Exchanges
Everus Price Tops $0.0139
Everus Price Tops $0.0139


© 2006-2019 Ticker Report